$REPH News

Last published 4y ago

4y agoREPH SCTLRecro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and TransformationGlobeNewswireWith Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society New Ticker (NASDAQ:SCTL) to Initiate Trading on March 22,
4y agoREPHRecro Reports Fourth Quarter and Year End 2021 Financial ResultsGlobeNewswireRecorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew by 147% Including IriSys Acquisition Company to
4y agoREPHRecro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego FacilityGlobeNewswireSAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges pri
4y agoREPHRecro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022GlobeNewswireSAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily i
4y agoREPHRecro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer PreventionGlobeNewswireSAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in
4y agoREPHRecro Appoints Eduardo Uribe as Head of Quality for Recro San DiegoGlobeNewswireSAN DIEGO and GAINESVILLE, Ga., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in
4y agoREPHRecro Reports Inducement Grants For New StaffGlobeNewswireSAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therap
4y agoREPHRecro to Present at H.C. Wainwright BioConnect 2022 ConferenceGlobeNewswireSAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in
4y agoREPHRecro to Present at Stephens Annual Investment ConferenceGlobeNewswireSAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily
5y agoREPHRecro Reports Third Quarter 2021 Financial ResultsGlobeNewswireAcquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2 Million and Signed Multiple New Business Ag
5y agoREPHRecro to Report Financial Results for Third Quarter 2021 on November 9, 2021GlobeNewswireSAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therap
5y agoREPHRecro Enters Into Master Commercial Supply and Services Agreement With OtsukaGlobeNewswireAgreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro's "Second Source" Strategy of Supporting Commercial Programs as U.S.-Based Supplier GAINESVILLE, Ga. and SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Recro Pharm
5y agoREPH VRPXRecro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray AnalgesicGlobeNewswireGAINESVILLE, Ga. and SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in
5y agoREPHRecro Reports Inducement Grants For New StaffGlobeNewswireEXTON, Penn. and SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in smal
5y agoREPHRecro Signs Renewable Energy Agreement With Georgia PowerGlobeNewswireEXTON, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic de
5y agoBICX REPHRecro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use DisorderGlobeNewswireSAN DIEGO and ANAHEIM, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small mole
5y agoREPHRecro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYSGlobeNewswireAcquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth Webcast Scheduled for 11:00 a.m. Eastern on Thursday, Augus
5y agoREPHRecro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMOGlobeNewswireCombination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms Transaction Expands Recro's Global Customer Base, Offer
5y agoREPHRecro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMOGlobeNewswireEXTON, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral s
5y agoREPHRecro To Report Financial Results for Second Quarter 2021 on August 9, 2021GlobeNewswireEXTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral s
5y agoREPHRecro Appoints Erica Raether as Vice President of People, Culture and ESGGlobeNewswireEXTON, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral s
5y agoREPHRecro Enters Development and Manufacturing Agreement With New ClientGlobeNewswireGAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing
5y agoREPHRecro Reports Inducement Grants for New StaffGlobeNewswireEXTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral s
5y agoREPHRecro Appoints Laura L. Parks, Ph.D. to Board of DirectorsGlobeNewswireEXTON, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral s
5y agoREPHRecro Expands Capabilities for Growing Clinical Trial Services (CTS) OfferingsGlobeNewswireGAINESVILLE, Ga., June 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing
5y agoREPHRecro Enters Development Agreement With Astex PharmaceuticalsGlobeNewswireEXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral soli
5y agoREPHRecro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireUnderwriters' Full Exercise of Option Brings Gross Proceeds to $34.5 Million EXTON, Pa., May 14, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving comp
5y agoREPHRecro Announces Pricing of $30.0 Million Public Offering of Common StockGlobeNewswireEXTON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid
5y agoREPHRecro Announces Proposed Public Offering of Common StockGlobeNewswireEXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid
5y agoREPHRecro Reports First Quarter 2021 Financial ResultsGlobeNewswireRevenues of $16.8 Million Represent an Increase of 70% Compared to Q4 2020 Revenue Multiple New Business Agreements Signed Facilities Expansion and Enhancements Continue Company to Host Conference Call Today at 4:30 p.m. ET EXTON, Pa., May 0
5y agoREPHRecro Pharma, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Recro Pharma, Inc. (NASDAQ:REPH) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time. To listen to the event live or access a rep
5y agoREPHRecro to Report Financial Results for First Quarter 2021 on May 6GlobeNewswireMALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral
5y agoREPH LACQRecro Expands Development and Manufacturing Relationship With Ensysce BiosciencesGlobeNewswireGAINESVILLE, Ga., April 15, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
5y agoREPHRecro Reports Inducement Grants for New StaffGlobeNewswireMALVERN, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
5y agoREPHRecro Strengthens Business Development Team to Drive Customer Growth and DiversificationGlobeNewswireSix Recent Hires Provide Broader Coverage and Expanded Capabilities in the Areas of Sales and Marketing Significant Traction Already Achieved in First Months of 2021 MALVERN, Pa., April 05, 2021 ...
5y agoREPHRecro to Present at H.C. Wainwright Global Life Science ConferenceGlobeNewswireMALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
5y agoREPHRecro Reports Fourth Quarter and Year End 2020 Financial ResultsGlobeNewswireStrengthened Industry-Centric Leadership Reorganization Initiated to Enhance Operations as Recro Expands Customer Portfolio, Explores Inorganic Growth Opportunities Core Commercial Product Outlook...
5y agoREPHRecro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously AnnouncedGlobeNewswireMALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
5y agoREPHRecro Announces Amendment to Athyrium Credit FacilityGlobeNewswireMALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
5y agoREPHRecro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26GlobeNewswireMALVERN, Pa., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
5y agoREPHRecro Strengthens Leadership Team With Key Executive and Board AppointmentsGlobeNewswireCompany Names CDMO Industry Thought Leader, Jim Miller, to Board of Directors and Selects Ryan D. Lake as Dedicated Chief Financial Officer Recent Appointments, including CEO David Enloe, Provide...
5y agoREPHRecro Grants Inducement Award to New Chief Executive OfficerGlobeNewswireMALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical...
5y agoREPHRecro Announces Executive ChangesGlobeNewswireMALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical...
6y agoREPHRecro Reports Third Quarter 2020 Financial ResultsGlobeNewswireCompany Secures Three-Year Renewal of License and Supply Agreement with Lannett, A Generics Pharmaceutical Company, for Manufacturing of Verelan PM®, Verelan SR® and Verapamil PM Strong Technical...
6y agoREPHRecro to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020GlobeNewswireMALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation,...
6y agoREPHRecro to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech SummitGlobeNewswireGAINESVILLE, Ga., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development,...
6y agoREPHRecro Reports Second Quarter 2020 Financial ResultsGlobeNewswireLaunches Clinical Trial Materials Business and Secures New Customers Company to Host Conference Call Today at 8:00 a.m. ET MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a...
6y agoREPHRecro to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020GlobeNewswireMALVERN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for development,...
6y agoREPHRecro Highlights Manufacturing Readiness For Essential Drugs and Medical SuppliesGlobeNewswireCompany Owns and Operates Over 120,000 Square Feet of U.S. cGMP and DEA-Licensed Contract Development and Manufacturing Facilities Focused on Creating Oral, Solid Dose Drug Products Long, Proven...
6y agoREPHRecro Pharma, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton; Investors Who Lost Money Should Contact the FirmGlobeNewswireBOSTON, May 11, 2020 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, announces that it has launched an investigation into potential securities...